rilotumumab
Showing 1 - 7 of 7
MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 Trial in United States
Terminated
- MET Positive
- +2 more
- Erlotinib Hydrochloride
- +2 more
-
Jonesboro, Arkansas
- +626 more
Mar 17, 2020
Treating Recurrent Stage IV Squamous Cell Lung Cancer
Active, not recruiting
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Docetaxel
- +12 more
-
Birmingham, Alabama
- +1003 more
Nov 29, 2021
Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer, Part 2- Advanced or Metastatic GEJ Trial in Japan
Completed
- Part 1- Advanced Solid Tumors
- +2 more
- Rilotumumab
-
Nagoya-shi, Aichi, Japan
- +6 more
Feb 26, 2016
Gastric Cancer Trial in Japan, Korea, Republic of (Rilotumumab, Placebo, Cisplatin)
Terminated
- Gastric Cancer
- Rilotumumab
- +3 more
-
Nagoya-shi, Aichi, Japan
- +24 more
Mar 4, 2016
Gastric Cancer Trial in Worldwide (Rilotumumab, Placebo, Epirubicin)
Terminated
- Gastric Cancer
- Rilotumumab
- +4 more
-
Tucson, Arizona
- +190 more
Jan 18, 2016
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma Trial (biological, drug, other)
Withdrawn
- Advanced Malignant Mesothelioma
- +3 more
- rilotumumab
- +3 more
- (no location specified)
Aug 1, 2013